Literature DB >> 23553633

Enhanced asynchronous Ca(2+) oscillations associated with impaired glutamate transport in cortical astrocytes expressing Fmr1 gene premutation expansion.

Zhengyu Cao1, Susan Hulsizer, Yanjun Cui, Dalyir L Pretto, Kyung Ho Kim, Paul J Hagerman, Flora Tassone, Isaac N Pessah.   

Abstract

BACKGROUND: FMR1 CGG expansion repeats in the premutation range have not been linked to astrocyte pathophysiology.
RESULTS: Premutation cortical astrocytes display decreased Glu transporter expression/activity and enhanced asynchronous Ca(2+) oscillations.
CONCLUSION: Glu transport and Ca(2+) signaling defects in premutation astrocytes could contribute to FXTAS neuropathology. SIGNIFICANCE: Premutation astrocytes may have an etiological role in FXTAS neuropathology. Premutation CGG repeat expansions (55-200 CGG repeats; preCGG) within the fragile X mental retardation 1 (FMR1) gene can cause fragile X-associated tremor/ataxia syndrome. Defects in early neuronal migration and morphology, electrophysiological activity, and mitochondria trafficking have been described in a premutation mouse model, but whether preCGG mutations also affect astrocyte function remains unknown. PreCGG cortical astrocytes (∼170 CGG repeats) displayed 3-fold higher Fmr1 mRNA and 30% lower FMR1 protein (FMRP) when compared with WT. PreCGG astrocytes showed modest reductions in expression of glutamate (Glu) transporters GLT-1 and GLAST and attenuated Glu uptake (p < 0.01). Consistent with astrocyte cultures in vitro, aged preCGG mice cerebral cortex also displayed reduced GLAST and GLT-1 expression. Approximately 65% of the WT and preCGG cortical astrocytes displayed spontaneous asynchronous Ca(2+) oscillations. PreCGG astrocytes exhibited nearly 50% higher frequency of asynchronous Ca(2+) oscillations (p < 0.01) than WT, a difference mimicked by chronic exposure of WT astrocytes to l-trans-pyrrolidine-2,4-dicarboxylic acid (l-trans-PDC) or by partial suppression of GLAST using siRNA interference. Acute challenge with Glu augmented the frequency of Ca(2+) oscillations in both genotypes. Additionally, 10 μm Glu elicited a sustained intracellular Ca(2+) rise in a higher portion of preCGG astrocytes when compared with WT. Pharmacological studies showed that mGluR5, but not NMDA receptor, contributed to Glu hypersensitivity in preCGG astrocytes. These functional defects in preCGG astrocytes, especially in Glu signaling, may contribute to fragile X-associated tremor/ataxia syndrome neuropathology.

Entities:  

Keywords:  Astrocytes; Ca2+ Oscillation; Calcium; FXTAS; Glutamate Transporter; Neurodegenerative Diseases; Neurological Diseases; Neurotransmitter Transport; Premutation CGG Expansion

Mesh:

Substances:

Year:  2013        PMID: 23553633      PMCID: PMC3650419          DOI: 10.1074/jbc.M112.441055

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Astrocytes prevent abnormal neuronal development in the fragile x mouse.

Authors:  Shelley Jacobs; Laurie C Doering
Journal:  J Neurosci       Date:  2010-03-24       Impact factor: 6.167

2.  The fragile X prevalence paradox.

Authors:  Paul J Hagerman
Journal:  J Med Genet       Date:  2008-04-15       Impact factor: 6.318

3.  Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.

Authors:  Faraz Farzin; Hazel Perry; David Hessl; Danuta Loesch; Jonathan Cohen; Susan Bacalman; Louise Gane; Flora Tassone; Paul Hagerman; Randi Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-04       Impact factor: 2.225

4.  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.

Authors:  David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

5.  CGG trinucleotide repeat length modulates neural plasticity and spatiotemporal processing in a mouse model of the fragile X premutation.

Authors:  Michael R Hunsaker; Kyoungmi Kim; Rob Willemsen; Robert F Berman
Journal:  Hippocampus       Date:  2012-06-18       Impact factor: 3.899

6.  Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate.

Authors:  J D Rothstein; M Dykes-Hoberg; C A Pardo; L A Bristol; L Jin; R W Kuncl; Y Kanai; M A Hediger; Y Wang; J P Schielke; D F Welty
Journal:  Neuron       Date:  1996-03       Impact factor: 17.173

7.  Reduction in glutamate uptake is associated with extrasynaptic NMDA and metabotropic glutamate receptor activation at the hippocampal CA1 synapse of aged rats.

Authors:  Brigitte Potier; Jean-Marie Billard; Sylvain Rivière; Pierre-Marie Sinet; Isabelle Denis; Gaelle Champeil-Potokar; Barbara Grintal; Anne Jouvenceau; Melanie Kollen; Patrick Dutar
Journal:  Aging Cell       Date:  2010-07-22       Impact factor: 9.304

8.  Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome.

Authors:  J R Brouwer; E Severijnen; F H de Jong; D Hessl; R J Hagerman; B A Oostra; R Willemsen
Journal:  Psychoneuroendocrinology       Date:  2008-05-12       Impact factor: 4.905

Review 9.  The FMR1 gene and fragile X-associated tremor/ataxia syndrome.

Authors:  J R Brouwer; R Willemsen; B A Oostra
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-09-05       Impact factor: 3.568

Review 10.  Lessons from fragile X regarding neurobiology, autism, and neurodegeneration.

Authors:  Randi J Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-02       Impact factor: 2.225

View more
  25 in total

Review 1.  General Anesthetic Use in Fragile X Spectrum Disorders.

Authors:  Andrew Ligsay; Marwa El-Deeb; Maria J Salcedo-Arellano; Nina Schloemerkemper; Jeremy S Grayson; Randi Hagerman
Journal:  J Neurosurg Anesthesiol       Date:  2019-07       Impact factor: 3.956

2.  Calcium dysregulation and Cdk5-ATM pathway involved in a mouse model of fragile X-associated tremor/ataxia syndrome.

Authors:  Gaëlle Robin; José R López; Glenda M Espinal; Susan Hulsizer; Paul J Hagerman; Isaac N Pessah
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 6.150

3.  Influence of tetramethylenedisulfotetramine on synchronous calcium oscillations at distinct developmental stages of hippocampal neuronal cultures.

Authors:  Zhengyu Cao; Jian Xu; Susan Hulsizer; Yanjun Cui; Yao Dong; Isaac N Pessah
Journal:  Neurotoxicology       Date:  2016-10-29       Impact factor: 4.294

Review 4.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

5.  Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome.

Authors:  Dalyir I Pretto; Madhur Kumar; Zhengyu Cao; Christopher L Cunningham; Blythe Durbin-Johnson; Lihong Qi; Robert Berman; Stephen C Noctor; Randi J Hagerman; Isaac N Pessah; Flora Tassone
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

Review 6.  Newborn screening for fragile X syndrome.

Authors:  Flora Tassone
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

7.  The Autism Spectrum Disorders Stem Cell Resource at Children's Hospital of Orange County: Implications for Disease Modeling and Drug Discovery.

Authors:  David J Brick; Hubert E Nethercott; Samantha Montesano; Maria G Banuelos; Alexander E Stover; Soleil Sun Schutte; Diane K O'Dowd; Randi J Hagerman; Michele Ono; David R Hessl; Flora Tassone; Philip H Schwartz
Journal:  Stem Cells Transl Med       Date:  2014-10-01       Impact factor: 6.940

Review 8.  Current research, diagnosis, and treatment of fragile X-associated tremor/ataxia syndrome.

Authors:  Zukhrofi Muzar; Reymundo Lozano
Journal:  Intractable Rare Dis Res       Date:  2014-11

Review 9.  Models to identify treatments for the acute and persistent effects of seizure-inducing chemical threat agents.

Authors:  Isaac N Pessah; Michael A Rogawski; Daniel J Tancredi; Heike Wulff; Dorota Zolkowska; Donald A Bruun; Bruce D Hammock; Pamela J Lein
Journal:  Ann N Y Acad Sci       Date:  2016-07-28       Impact factor: 5.691

Review 10.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.